The importance of alpha/beta (α/β) interferon receptors and signaling pathways for the treatment of cervical intraepithelial neoplasias

Introduction: Immunotherapies have been effective in treating various forms of cancer, including cervical intraepithelial neoplasias (CINs) predominantly caused by human papilloma virus (HPV). Development: To establish persistent infections in stratified epithelia, HPV induces proliferative lesions. Viral gene products are able to change gene expression and cellular proteins. Interferons (IFNs) are inducible glycoproteins that have immunomodulatory, antiviral, antiproliferative, and antiangiogenic effects. In particular, interferon-alpha (IFN-α) has been shown to inhibit the development and progression of cervical cancer. In this review, actions of interferons α/beta (α/β), including their receptors and signaling pathways, are described, as well as their clinical importance in the immune response against cervical lesions. Conclusion: The interaction of IFN-α/β with its receptor results in a series of phosphorylation events. These mechanisms can be ineffective in IFN response, then it can also compromise the therapeutic effects of immunotherapy.

Type I Interferons; Interferon receptors; Cervical neoplasia.

[1] Schiffman M.H., Bauer H.M., Hoover R.N., Glass A.G., Cadell D. M., Rush B.B., et al.: “Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia”. J. Natl. Cancer Inst., 1993; 85, 958.

[2] Shingleton H.M., Richart R.M., Wiener J., Spiro D.: “Human cervical intraepithelial neoplasia: fine structure of dysplasia and carcinoma in situ”. Cancer Res., 1968, 28, 695.

[3] Hong S., Mehta K.P., Laimins L.A.: “Suppression of STAT-1 expression by human papillomaviruses is necessary for differentiation-dependent genome amplification and plasmid maintenance”. J. Virol., 2011, 85, 9486.

[4] Goubau D., Romieu-Mourez R., Solis M., Hernandez E., Mesplènde T., Lin R., et al.:“Transcriptional re-programming of primary macrophages reveals distinct apoptotic and anti-tumoral functions of IRF-3 and IRF-7”. Eur. J. Immunol. ,2009, 39, 527.

[5] Boccardo E., Lepique A.P., Villa L.L.: “The role of inflammation in HPV carcinogenesis”. Carcinogenesis, 2010, 31, 1905.

[6] Levy D.E., Darnell J.E.: “Interferon-dependent transcriptional activation: signal transduction without second messenger involvement?” New Biol., 1990, 2, 923.

[7] Darnell J.E.: “STATs and gene regulation”. Science, 1997, 277, 1630.

[8] Darnell J.E. Jr., Kerr I.M., Stark G.R.: “Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins”. Science, 1994, 264, 1415.

[9] Horvath C.M., Darnell J.E. Jr.: “The antiviral state induced by alpha interferon and gamma interferon requires transcriptionally active stat1 protein”. J. Virol., 1996, 70, 647.

[10] Novick D., Cohen B., Rubinstein M.: “The human interferon alpha/beta receptor: characterization and molecular cloning”. Cell. 1994, 77, 391.

[11] Kim S.H., Cohen B., Novick D., Rubinstein M.: “Mammalian type I interferon receptors consists of two subunits: IFNaR1 and IFNaR2”. Gene, 1997, 196, 279.

[12] Ghislain J., Sussman G., Goelz S., Ling L.E., Fish E.N.: “Configuration of the interferon-α/β receptor complex determines the context of the biological response”. J. Biol. Chem., 1995, 270, 21785.

[13] Moraga I., Harari D., Schreiber G., Uzé G., Pellegrini S.: “Receptor density is key to the alpha2/beta interferon differential activities”. Mol. Cell. Biol., 2009, 17, 4778.

[14] Liu J., Plotnikov A., Banerjee A., Suresh Kumar K.G., Ragimbeau J., Marijanovic Z., et al.:“Ligand-independent pathway that controls stability of interferon alpha receptor”. Biochem. Biophys. Res. Commun., 2008, 367, 388.

[15] Ramos M.C., Mardegan M.C., Peghini B.C., Adad S.J., Michelin M. A., Murta E.F.C.: “Expression of cytokines in cervical stroma in patients with high-grade cervical intraepithelial neoplasia after treatment with intralesional interferon alpha-2b”. Eur. J. Gynaecol. Oncol., 2010, 31, 522.

[16] Mardegan M.C., Ramos M.C., Adad S.J., Michelin M.A., Shimba D., Murta E.F.: “Immunological evaluation of vaginal secretion in patients with high-grade cervical intraepithelial neoplasia treated with intralesional interferon alpha-2b”. Eur. J. Gynaecol. Oncol., 2011, 32, 297.

[17] Tirone N.R., Peghini B.C., Barcelos A.C.M., Murta E.F.C., Michelin M.A.: “Local expression of interferon-alpha and interferon receptors in cervical intraepithelial neoplasia”. Cancer Immunol. Immunother., 2009, 58, 2003.

[18] Ota H., Nagano H., Sakon M., Eguchi H., Kondo M., Yamamoto T., et al.: “Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-alpha and intra-arterial 5-fluorouracil; role of type 1 interferon receptor expression”. Br. J. Cancer, 2005, 93, 557.

[19] Vitale G., van Eijck C.H., van Koetsveld Ing. P.M., Erdmann J.I., Speel E.J., Van Wansem Ing. K., et al.:“Type Iinterferons in the treatment of pancreatic cancer. Mechanisms of action and role of related receptors”. Ann. Surg., 2007, 246, 259.

[20] Chang Y.E., Laimins L.A.: “Microarray analysis identifies interferon-inducible genes and Stat-1 as major transcriptional targets of human papillomavirus type 31”. J. Virol., 2000, 74, 4174.

[21] Hiscott J.: “Triggering the innate antiviral response through IRF-3 activation”. J. Biol. Chem., 2007, 282, 15325.

[22] Alarcón-Riquelme M.: “Nucleic acid by-products and chronic inflammation”. Nat Genet., 2006, 38, 866.

[23] Murata M., Nabeshima S., Kikuchi K., Yamaji K., Furusyo N., Hayashi J.: “A comparison of the antitumor effects of interferon-α and β on human hepatocellular carcinoma cell lines”. Cytokine, 2006, 33, 121.

[24] Murta E.F.C., Tavares-Murta B.M.: “Successful pregnancy after vaginal cancer treated with interferon”. Tumori, 2004, 90, 247.

[25] Kim K.Y., Blatt L., Taylor M.W.: “The effects of interferon on the expression of human papillomavirus oncogenes”. J. Gen. Virol., 2000, 81, 695.

[26] Woodworth C.D., Simpson S.: “Comparative lymphokine secretion by cultured normal human cervical keratinocytes, papillomavirus-immortalized, and carcinoma cell lines”. Am. J. Pathol., 1993, 142,1544.

[27] Prchal-Murphy M., Semper C., Lassnig C., Wallner B., Gausterer C., Teppner-Klymiuk I., et al.: “TYK2 kinase activity is required for functional type I interferon responses in vivo”. Plos. One, 2012, 7, 1.

[28] Bromberg J.F., Horvath C.M., Wen Z., Schreiber R.D., Darnell J.E. Jr.: “Transcriptionally active STAT1 is required for the antiproliferative effects of both interferon-α and interferon-γ”. Proc. Natl. Acad. Sci. U S A, 1996, 93, 7673.

[29] Uzé G., Lutfalla G., Bandu M.T., Proudhon D., Mogensen K.E.: “Behaviour of a cloned murine interferon alpha/beta receptor expressed in homospecific or heterospecific background”. Proc. Natl. Acad. Sci. U S A, 1992, 89, 4774.

[30] He X., Chang Y., Jiang H., Tang F., Meng F., Xie Q., et al.: “Persistent effect of IFNAR-1 genetic polymorphism on the long-term pathogenesis of chronic HBV infection”. Viral. Immunol., 2010, 23, 251.

[31] Hsieh C.S., Macatonia S.E., Tripp C.S., Wolf S.F., O’garra A., Murphy K.M.: “Development of TH1 CD4+ T cells through IL-12 produced by Listeria induced macrophages”. Science, 1993, 260, 547.

[32] Müller U., Steinhoff U., Reis L.F.L., Hemmi S., Paviovic J., Zinkernagel R.M., et al.: “Functional role of type I and type II interferons in antiviral defense”. Science, 1994, 264, 1918.

[33] Kotenko S.V., Gallagher G., Baurin V.V., Lewis-Antes A., Shen M., Shah N.K., et al.:“IFN-λs mediate antiviral protection through a distinct class II cytokine receptor complex”. Nat. Immunol., 2003, 4, 69.

[34] Aaronson D.S., Horvath C.M.: “A road map for those who don’t know JAK-STAT”. Science, 2002, 296, 1653.